|
US2019016682A1
|
|
Azepane derivatives and methods of treating hepatitis B infections
|
|
WO2018064675A1
|
|
Metabolic restriction in cell-based assays
|
|
WO2018005881A1
|
|
Oxadiazepinone derivatives and their use in the treatment of hepatitis b infections
|
|
WO2018005883A1
|
|
Diazepinone derivatives and their use in the treatment of hepatitis b infections
|
|
KR20180129943A
|
|
Formulations and methods involving capsid assembly inhibitors
|
|
EP3356328A1
|
|
Crystalline forms of a hepatitis b antiviral agent
|
|
AU2016232801A1
|
|
Azocane and azonane derivatives and methods of treating hepatitis B infections
|
|
EP3240787A2
|
|
Derivatives and methods of treating hepatitis b infections
|
|
AU2015358561A1
|
|
Sulfide alkyl and pyridyl reverse sulfonamide compounds for HBV treatment
|
|
US2016185748A1
|
|
Pyridyl reverse sulfonamides for HBV treatment
|
|
US2016151375A1
|
|
Sulfide alkyl compounds for HBV treatment
|
|
US2015274652A1
|
|
Piperidine derivatives and methods of treating hepatitis B infections
|
|
KR20160128305A
|
|
Combination therapy for treatment of hbv infections
|
|
US2015197533A1
|
|
Azepane derivatives and methods of treating hepatitis B infections
|
|
KR20160127714A
|
|
Azepane derivatives and methods of treating hepatitis b infections
|
|
US2015197493A1
|
|
Azepane derivatives and methods of treating hepatitis B infections
|
|
US2014275167A1
|
|
Hepatitis B antiviral agents
|
|
NZ724493A
|
|
Hepatitis b antiviral agents
|
